APOE and Alzheimer disease: These anomalies are independent of amyloid-β [1,9], insinuating that breakdown of the BBB contributes to ApoE4-associated cognitive decline independently of the AD classic pathology, and might be a therapeutic target in ApoE4 carriers [1].